Medicina
Departamento
Vita-Salute San Raffaele University
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Vita-Salute San Raffaele University (8)
2023
-
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
HemaSphere
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia
2021
-
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Journal of Neurology, Vol. 268, Núm. 11, pp. 3961-3968
2020
2010
-
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies
The Lancet, Vol. 375, Núm. 9733, pp. 2215-2222